A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
Latest Information Update: 30 Dec 2024
At a glance
- Drugs Berzosertib (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 11 Dec 2024 Planned End Date changed from 1 Jul 2024 to 9 Dec 2025.
- 04 Jul 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 04 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.